Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

NCT05976893 is registered in ClinicalTrials.gov with Xiang Xie as lead sponsor.

NCT NCT05976893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05976893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Lead sponsor
Xiang Xie
Phase
Phase 4
Overall status
Unknown status
Start date
August 1, 2023
Completion date
December 31, 2025
Enrollment
620 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ascvd, atherosclerotic cardiovascular disease, cancer, proprotein convertase subtilisin/kexin type 9 inhibitor